A phase I trial of the human double minute 2 (HDM2) inhibitor MK-8242 in patients (pts) with advanced solid tumors.

被引：0
|
作者：
Wagner, Andrew J.
Banerji, Udai
Mahipal, Amit
Somaiah, Neeta
Hirsch, Heather Anne
Fancourt, Craig
Levonas, Amy
Lam, Raymond
Meister, Amy
Kemp, Ramon Karmel
Knox, Clayton
Rose, Shelonitda
Hong, David S.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Inst Canc Res, London SW3 6JB, England
[3] Royal Marsden NHS Fdn Trust, London, England
[4] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Sarcoma Med Oncol, Houston, TX 77030 USA
[6] Merck & Co Inc, Kenilworth, NJ USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Program 1, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10564
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Gemcitabine and Docetaxel in patients with advanced solid tumors. A GETICS phase I trial
    Jaremtchuk, AV
    Zabra, JJ
    Ferro, A
    Aman, EF
    Alvarez, R
    Arroyo, G
    Marmissolle, F
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S290 - S290
  • [22] Phase I trial of ADI-peg 20 plus docetaxel (DOC) in patients (pts) with advanced solid tumors.
    Tomlinson, Ben Kent
    Bomalaski, John S.
    Diaz, Monica
    Akande, Taiwo
    Mahaffey, Nichole
    Li, Tianhong
    Dutia, Mrinal P.
    Kelly, Karen
    Gong, I-Yeh
    Gandara, David R.
    Pan, Chong-xian
    Lara, Primo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [23] Phase I trial of CT-2106 (polyglutamated camptothecin) administered weekly in patients (pts) with advanced solid tumors.
    Daud, A.
    Garrett, C.
    Simon, G. R.
    Munster, P.
    Sullivan, D.
    Stromatt, S.
    Allevi, C.
    Bernareggi, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 82S - 82S
  • [24] Phase I pharmacokinetic, and pharmacodynamic trial of the novel oral notch inhibitor MK-0752 in patients with advanced breast cancer and other solid tumors.
    Krop, I. E.
    Kosh, M.
    Fearen, I
    Savoie, J.
    Dallob, A.
    Stone, J.
    Winer, E.
    Freedman, S. J.
    LoRusso, P.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S287 - S287
  • [25] A phase I study of IPI-926, a novel hedgehog pathway inhibitor, in patients (pts) with advanced or metastatic solid tumors.
    Rudin, C. M.
    Jimeno, A.
    Miller, W. H.
    Eigl, B. J.
    Gettinger, S. N.
    Chang, A. L. S.
    Faia, K.
    Sweeney, J.
    Loewen, G.
    Ross, R. W.
    Weiss, G. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [26] Phase I study of receptor tyrosine kinase (RTK) inhibitor, MGCD265, in patients (pts) with advanced solid tumors.
    Kollmannsberger, Christian K.
    Sharma, Sunil
    Shapiro, Geoffrey
    Chi, Kim N.
    Christensen, James
    Tassell, Vanessa Roberts
    Chao, Richard C.
    Faltaos, Demiana
    Hurwitz, Herbert
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [27] A phase I trial of MK-2206 and hydroxychloroquine in patients with advanced solid tumors
    Mehnert, Janice M.
    Kaveney, Amanda D.
    Malhotra, Jyoti
    Spencer, Kristen
    Portal, Daniella
    Goodin, Susan
    Tan, Antoinette R.
    Aisner, Joseph
    Moss, Rebecca A.
    Lin, Hongxia
    Bertino, Joseph R.
    Gibbon, Darlene
    Doyle, Laurence A.
    White, Eileen P.
    Stein, Mark N.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (04) : 899 - 907
  • [28] A phase I trial of MK-2206 and hydroxychloroquine in patients with advanced solid tumors
    Janice M. Mehnert
    Amanda D. Kaveney
    Jyoti Malhotra
    Kristen Spencer
    Daniella Portal
    Susan Goodin
    Antoinette R. Tan
    Joseph Aisner
    Rebecca A. Moss
    Hongxia Lin
    Joseph R. Bertino
    Darlene Gibbon
    Laurence A. Doyle
    Eileen P. White
    Mark N. Stein
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 899 - 907
  • [29] Phase I trial of IACS-010759 (IACS), a potent, selective inhibitor of complex I of the mitochondrial electron transport chain, in patients (pts) with advanced solid tumors.
    Yap, Timothy A.
    Ahnert, Jordi Rodon
    Piha-Paul, Sarina Anne
    Fu, Siqing
    Janku, Filip
    Karp, Daniel D.
    Naing, Aung
    Dumbrava, Ecaterina Elena Ileana
    Pant, Shubham
    Subbiah, Vivek
    Tsimberidou, Apostolia Maria
    Hong, David S.
    Rose, Kelsey Meagan
    Xu, Quanyun
    Vellano, Christopher P.
    Mahendra, Mikhila
    Jones, Philip
    Di Francesco, Maria Emilia
    Marszalek, Joseph R.
    Meric-Bernstam, Funda
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [30] First-in-class, first-in-human phase I trial of KPT-330, a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors.
    Razak, Albiruni R. A.
    Soerensen, Morten Mau
    Mahipal, Amit
    Shacham, Sharon
    Yau, Cindy Y. F.
    Lassen, Ulrik Niels
    McCauley, Dilara
    Cooksey, Jennifer
    Tan, David Shao Peng
    Saint-Martin, Jean-Richard
    Landesman, Yossi
    Pond, Gregory
    Oza, Amit M.
    Kauffman, Michael
    Siu, Lillian L.
    Mirza, Mansoor Raza
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345